Geode Capital Management, LLC Annovis Bio, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 99,114 shares of ANVS stock, worth $433,128. This represents 0.0% of its overall portfolio holdings.

Number of Shares

99,114

Previous 76,233 30.01%

Holding current value

$433,128

Previous $439,000 81.78%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$5.27 - $15.46 $120,582 - $353,740	22,881 Added 30.01%	99,114 $798,000
Q2 2024 Aug 09, 2024	BUY	$4.82 - $18.01 $26,230 - $98,010	5,442 Added 7.69%	76,233 $439,000
Q1 2024 May 13, 2024	BUY	$8.47 - $18.93 $17,067 - $38,143	2,015 Added 2.93%	70,791 $842,000
Q4 2023 Feb 13, 2024	BUY	$5.55 - $19.62 $70,684 - $249,880	12,736 Added 22.73%	68,776 $1.29 Million
Q3 2023 Nov 13, 2023	BUY	$9.37 - $14.12 $41,134 - $61,986	4,390 Added 8.5%	56,040 $531,000
Q1 2023 May 15, 2023	BUY	$12.33 - $22.1 $99,774 - $178,833	8,092 Added 18.58%	51,650 $795,000
Q4 2022 Feb 13, 2023	BUY	$10.99 - $13.8 $13,869 - $17,415	1,262 Added 2.98%	43,558 $584,000
Q2 2022 Aug 12, 2022	BUY	$8.61 - $13.87 $2,316 - $3,731	269 Added 0.64%	42,296 $479,000
Q1 2022 May 13, 2022	BUY	$11.84 - $19.78 $12,810 - $21,401	1,082 Added 2.64%	42,027 $561,000
Q3 2021 Nov 12, 2021	BUY	$30.95 - $120.97 $73,537 - $287,424	2,376 Added 6.16%	40,945 $1.3 Million
Q2 2021 Aug 13, 2021	BUY	$21.55 - $96.1 $236,748 - $1.06 Million	10,986 Added 39.83%	38,569 $3.3 Million
Q1 2021 May 12, 2021	BUY	$8.15 - $38.44 $224,801 - $1.06 Million	27,583 New	27,583 $769,000

Others Institutions Holding ANVS

# of Institutions

Shares Held

1.17M

Call Options Held

229K

Put Options Held

934K

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $35.7M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Annovis Bio, Inc. Transaction History